Patients with AFP decrease >50% had longer PFS and OS; however, these measures did not reach statistical significance (Supplementary Fig. 1 ).
← all excerpts
A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.
1
—
—